@mallatlab.bsky.social
Reposted
January 12, 2026 at 6:30 PM
Reposted
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
January 12, 2026 at 7:05 PM
The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️🔥 at 2 years
PAPER ALERT: The IVORY trial published in Nature Medicine last week: rdcu.be/eX8W3
@ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social
@ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social
January 12, 2026 at 11:58 AM
PAPER ALERT: The IVORY trial published in Nature Medicine last week: rdcu.be/eX8W3
@ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social
@ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social
Reposted
January 12, 2026 at 10:06 AM
Reposted
Thank you @danieljdrucker.bsky.social for highlighting our work. This may be a game changer!
Nature Medicine: rdcu.be/eX8W3
Nature Medicine: rdcu.be/eX8W3
January 12, 2026 at 10:16 AM
Thank you @danieljdrucker.bsky.social for highlighting our work. This may be a game changer!
Nature Medicine: rdcu.be/eX8W3
Nature Medicine: rdcu.be/eX8W3
Reposted
Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...
Learn More: www.nature.com/articles/s41...
Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine
In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...
www.nature.com
January 8, 2026 at 1:56 PM
Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...
Learn More: www.nature.com/articles/s41...
Reposted